HUM vs IQV

Humana exhibits significant fundamental weakness, highlighted by a Piotroski F-Score of 3/9, indicating poor financial health. The stock is trading at a substantial premium to both its Graham Number ($179.96) and its growth-based Intrinsic Value ($68.81). While revenue growth remains positive at 11.3%, this is completely offset by a catastrophic collapse in earnings growth (-206% YoY) and negative operating margins. The recent 1-month price surge appears disconnected from the long-term bearish trend and deteriorating profitability metrics.

IQVIA exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a highly attractive PEG ratio of 0.68, suggesting significant undervaluation relative to its growth. While the stock is currently trading at a premium to its Graham Number ($82.24), it sits well below its intrinsic value ($231.28) and analyst targets ($231.60). However, the bullish fundamental outlook is contrasted by a severe technical downtrend and liquidity concerns, evidenced by a current ratio of 0.75 and high leverage. Overall, the company's robust ROE and consistent earnings growth make it a strong value play despite short-term price volatility.